07:00 , Sep 15, 2016 |  BC Innovations  |  Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc.'s anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical and...
08:00 , Jan 21, 2016 |  BC Innovations  |  Finance

Italy's velocity factor

After five years of building a portfolio of research programs, Italian tech transfer company TTFactor s.r.l. can now turn to a homegrown supply of seed funding following the launch of BiovelocITA, the country's first biotech...
08:00 , Nov 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) G protein-coupled receptor 17 (GPR17) Cell culture studies suggest inhibiting GPR17 could...
07:00 , May 6, 2013 |  BC Week In Review  |  Clinical News

Omeros preclinical data

In a mouse model of experimental autoimmune encephalomyelitis (EAE), a series of G protein-coupled receptor 17 (GPR17) antagonists significantly improved disease progression as measured by motor dysfunction vs. untreated controls. Omeros declined to disclose...
07:00 , Jul 19, 2012 |  BC Innovations  |  Targets & Mechanisms

Getting AGRP on obesity

Researchers in New York have identified G protein-coupled receptor 17 as a target on agouti related protein-expressing neurons, which are known to regulate multiple factors related to obesity.1 The findings open up a new molecular...
07:00 , Jun 21, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Agouti related protein (AGRP); forkhead box O1 (FOXO1); G protein-coupled receptor 17 (GPR17) Mouse and...